Preliminary validation and clinical meaning of the cutaneous assessment tool in juvenile dermatomyositis

Arthritis Care and Research

Volumn 59, Issue 2, 2008, Pages 214-221

  Huber, Adam M ^a,o   Dugan, Elizabeth M ^b   Lachenbruch, Peter A ^c,d   Feldman, Brian M ^e   Perez, Maria D ^f   Zemel, Lawrence S ^g   Lindsley, Carol B ^h   Rennebohm, Robert M ⁱ   Wallace, Carol A ^j   Passo, Murray H ^k   Reed, Ann M ^l   Bowyer, Suzanne L ^m   Ballinger, Susan H ^m   Miller, Frederick W ⁿ   Rider, Lisa G ⁿ  

^a DALHOUSIE UNIVERSITY   (Canada)

^b WASHINGTON HOSPITAL CENTER   (United States)

^c OREGON STATE UNIVERSITY   (United States)

^d CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^e HOSPITAL FOR SICK CHILDREN   (Canada)

^f BAYLOR COLLEGE OF MEDICINE   (United States)

^g UNIVERSITY OF CONNECTICUT   (United States)

^h UNIVERSITY OF KANSAS   (United States)

ⁱ OHIO STATE UNIVERSITY   (United States)

^j UNIVERSITY OF WASHINGTON   (United States)

^k UNIVERSITY OF CINCINNATI   (United States)

^l MAYO CLINIC   (United States)

^m INDIANA UNIVERSITY   (United States)

ⁿ NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^o IWK HEALTH CENTRE   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CHILD; CONSTRUCT VALIDITY; CONTROLLED STUDY; CRONBACH ALPHA COEFFICIENT; DERMATOMYOSITIS; DISEASE ACTIVITY; DISEASE SEVERITY; ENDOREDUPLICATION; HUMAN; INTERNAL CONSISTENCY; ITEM TOTAL CORRELATION; MAJOR CLINICAL STUDY; PREDICTION;

ACUTE DISEASE; CHILD; CHRONIC DISEASE; DERMATOMYOSITIS; FOLLOW-UP STUDIES; HUMANS; MYOSITIS; PILOT PROJECTS; REPRODUCIBILITY OF RESULTS; SEVERITY OF ILLNESS INDEX; SKIN;

EID: 39449137046     PISSN: 21514658     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.23340     Document Type: Article

References (19)

1. Callen JP. Dermatomyositis. Lancet 2000;355:53-7.
2. Santmyire-Rosenberger B, Dugan EM. Skin involvement in dermatomyositis. Curr Opin Rheumatol 2003;15:714-22.
3. Sontheimer RD. Skin manifestations of systemic autoimmune connective tissue disease: diagnostics and therapeutics. Best Pract Res Clin Rheumatol 2004;18:429-62.
4. Huber AM, Hicks JE, Lachenbruch PA, Perez MD, Zemel LS, Rennebohm RM, et al. Validation of the Childhood Health Assessment Questionnaire in the juvenile idiopathic inflammatory myopathies. J Rheumatol 2001;28:1106-11.
5. Huber AM, Feldman BM, Rennebohm RM, Hicks JE, Lindsley CB, Perez MD, et al. for the Juvenile Dermatomyositis Disease Activity Collaborative Study Group. Validation and clinical significance of the Childhood Myositis Assessment Scale for assessment of muscle function in the juvenile idiopathic inflammatory myopathies. Arthritis Rheum 2004;50:1595-603.
6. Hundley JL, Carroll CL, Lang W, Snively B, Yosipovitch G, Feldman SR, et al. Cutaneous symptoms of dermatomyositis significantly impact patients' quality of life. J Am Acad Dermatol 2006;54:217-20.
7. Huber AM, Lang B, LeBlanc CM, Birdi N, Bolaria RK, Malleson P, et al. Medium- and long-term functional outcomes in a multicenter cohort of children with juvenile dermatomyositis. Arthritis Rheum 2000;43:541-9.
8. Miller FW, Rider LG, Chung YL, Cooper R, Danko K, Farewell V, et al, and the International Myositis Outcome Assessment Collaborative Study Group. Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathy. Rheumatology (Oxford) 2001;40:1262-73.
9. Ruperto N, Ravelli A, Murray K, Lovell DJ, Andersson-Gare B, Feldman BM, et al, the Paediatric Rheumatology International Trials Organization (PRINTO), and the Pediatric Rheumatology Collaborative Study Group (PRCSG). Preliminary core sets of measures for disease activity and damage assessment in juvenile systemic lupus erythematosus and juvenile dermatomyositis. Rheumatology (Oxford) 2003;42:1452-9.
10. Huber AM, Dugan EM, Lachenbruch PA, Feldman BM, Perez MD, Zemel LS, et al, in cooperation with the Juvenile Dermatomyositis Disease Activity Collaborative Study Group. The Cutaneous Assessment Tool: development and reliability in juvenile idiopathic inflammatory myopathy. Rheumatology (Oxford) 2007;46:1606-11.
11. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975;292:344-7.
12. Rider LG, Feldman BM, Perez MD, Rennebohm RM, Lindsley CB, Zemel LS, et al, in cooperation with the Juvenile Dermatomyositis Disease Activity Collaborative Study Group. Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies. I. Physician, parent and patient global assessments. Arthritis Rheum 1997;40:1976-83.
13. Lovell DJ, Lindsley CB, Rennebohm RM, Ballinger SH, Bowyer SL, Giannini EH, et al, in cooperation with the Juvenile Dermatomyositis Disease Activity Collaborative Study Group. Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies. II. The Childhood Myositis Assessment Scale (CMAS): a quantitative tool for the evaluation of muscle function. Arthritis Rheum 1999;42:2213-9.
14. Nunnally JC. Psychometric theory. 2nd ed. New York: McGraw-Hill; 1978.
15. Streiner DL, Norman GR. Health measurement scales: a practical guide to their development and use. 3rd ed. New York: Oxford University; 2003.
16. Beaton DE, Hogg-Johnson S, Bombardier C. Evaluating changes in health status: reliability and responsiveness of five generic health status measures in workers with musculoskeletal disorders. J Clin Epidemiol 1997;50:79-93.
17. Dhanani S, Quenneville J, Perron M, Abdolell M, Feldman BM. Minimal difference in pain associated with change in quality of life in children with rheumatic disease. Arthritis Rheum 2002;47:501-5.
18. O'Connor K, Abbott K, Sabin B, Kuroda M, Pachman LM. MxA gene expression in juvenile dermatomyositis peripheral blood mononuclear cells: association with muscle involvement. Clin Immunol 2006;120:319-25.
19. Smith R, Sundberg J, Shamiyah E, Dyer A, Pachman LM. Skin involvement in juvenile dermatomyositis is associated with loss of end row nailfold capillary loops. J Rheumatol 2004;31:1644-9.